Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Page: 117
Published Date: 04 Jan 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size was valued at USD 789.2 million in 2023 and is forecast to a readjusted size of USD 1123 million by 2030 with a CAGR of 5.2% during review period.
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy industry chain, the market status of Hemophilia (Single-stranded AAV (ssAAV), Self-complementary AAV (scAAV)), Ophthalmology (Single-stranded AAV (ssAAV), Self-complementary AAV (scAAV)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.
Regionally, the report analyzes the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Single-stranded AAV (ssAAV), Self-complementary AAV (scAAV)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.
Regional Analysis: The report involves examining the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Adeno-Associated Virus (AAV) Vector-Based Gene Therapy:
Company Analysis: Report covers individual Adeno-Associated Virus (AAV) Vector-Based Gene Therapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Adeno-Associated Virus (AAV) Vector-Based Gene Therapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hemophilia, Ophthalmology).
Technology Analysis: Report covers specific technologies relevant to Adeno-Associated Virus (AAV) Vector-Based Gene Therapy. It assesses the current state, advancements, and potential future developments in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Market segment by Application
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Market segment by players, this report covers
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, with revenue, gross margin and global market share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy from 2019 to 2024.
Chapter 3, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.
Chapter 13, to describe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type
1.3.1 Overview: Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Type in 2023
1.3.3 Single-stranded AAV (ssAAV)
1.3.4 Self-complementary AAV (scAAV)
1.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market by Application
1.4.1 Overview: Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hemophilia
1.4.3 Ophthalmology
1.4.4 Lysosomal Storage Disorders
1.4.5 Neurological Disorders
1.4.6 Others
1.5 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size & Forecast
1.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast by Region
1.6.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region, (2019-2030)
1.6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2019-2030)
1.6.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2019-2030)
1.6.6 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Prospect (2019-2030)
2.1 BioMarin Pharmaceutical
2.1.1 BioMarin Pharmaceutical Details
2.1.2 BioMarin Pharmaceutical Major Business
2.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.1.4 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 BioMarin Pharmaceutical Recent Developments and Future Plans
2.2 Sangamo Therapeutics
2.2.1 Sangamo Therapeutics Details
2.2.2 Sangamo Therapeutics Major Business
2.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.2.4 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Sangamo Therapeutics Recent Developments and Future Plans
2.3 Amicus Therapeutics
2.3.1 Amicus Therapeutics Details
2.3.2 Amicus Therapeutics Major Business
2.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Amicus Therapeutics Recent Developments and Future Plans
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.4.4 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Roche Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.5.4 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 NightstaRx
2.6.1 NightstaRx Details
2.6.2 NightstaRx Major Business
2.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.6.4 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 NightstaRx Recent Developments and Future Plans
2.7 MeiraGTx
2.7.1 MeiraGTx Details
2.7.2 MeiraGTx Major Business
2.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.7.4 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 MeiraGTx Recent Developments and Future Plans
2.8 Sarepta Therapeutics
2.8.1 Sarepta Therapeutics Details
2.8.2 Sarepta Therapeutics Major Business
2.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.8.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Sarepta Therapeutics Recent Developments and Future Plans
2.9 Neurocrine Biosciences
2.9.1 Neurocrine Biosciences Details
2.9.2 Neurocrine Biosciences Major Business
2.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.9.4 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Neurocrine Biosciences Recent Developments and Future Plans
2.10 Voyager Therapeutics
2.10.1 Voyager Therapeutics Details
2.10.2 Voyager Therapeutics Major Business
2.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.10.4 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Voyager Therapeutics Recent Developments and Future Plans
2.11 Asklepios Biopharmaceutical
2.11.1 Asklepios Biopharmaceutical Details
2.11.2 Asklepios Biopharmaceutical Major Business
2.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
2.11.4 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Asklepios Biopharmaceutical Recent Developments and Future Plans
3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Company Revenue
3.2.2 Top 3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share in 2023
3.2.3 Top 6 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share in 2023
3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Overall Company Footprint Analysis
3.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Region Footprint
3.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Company Product Type Footprint
3.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value and Market Share by Type (2019-2024)
4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Type (2025-2030)
5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Application (2019-2024)
5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Application (2025-2030)
6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2030)
6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2030)
6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
6.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2019-2030)
6.3.2 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
6.3.3 Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
6.3.4 Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2030)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2030)
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
7.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2019-2030)
7.3.2 Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
7.3.3 France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
7.3.5 Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
7.3.6 Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.3.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Region (2019-2030)
8.3.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
8.3.3 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
8.3.4 South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
8.3.5 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
8.3.7 Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
9.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2030)
9.2 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2030)
9.3 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
9.3.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2019-2030)
9.3.2 Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
9.3.3 Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
10.3.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2019-2030)
10.3.2 Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
10.3.4 UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Forecast (2019-2030)
11.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
11.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
11.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain
12.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Upstream Analysis
12.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Midstream Analysis
12.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Region (2025-2030) & (USD Million)
Table 5. BioMarin Pharmaceutical Company Information, Head Office, and Major Competitors
Table 6. BioMarin Pharmaceutical Major Business
Table 7. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 8. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. BioMarin Pharmaceutical Recent Developments and Future Plans
Table 10. Sangamo Therapeutics Company Information, Head Office, and Major Competitors
Table 11. Sangamo Therapeutics Major Business
Table 12. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 13. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Sangamo Therapeutics Recent Developments and Future Plans
Table 15. Amicus Therapeutics Company Information, Head Office, and Major Competitors
Table 16. Amicus Therapeutics Major Business
Table 17. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 18. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Amicus Therapeutics Recent Developments and Future Plans
Table 20. Roche Company Information, Head Office, and Major Competitors
Table 21. Roche Major Business
Table 22. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 23. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Roche Recent Developments and Future Plans
Table 25. Pfizer Company Information, Head Office, and Major Competitors
Table 26. Pfizer Major Business
Table 27. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 28. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Pfizer Recent Developments and Future Plans
Table 30. NightstaRx Company Information, Head Office, and Major Competitors
Table 31. NightstaRx Major Business
Table 32. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 33. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. NightstaRx Recent Developments and Future Plans
Table 35. MeiraGTx Company Information, Head Office, and Major Competitors
Table 36. MeiraGTx Major Business
Table 37. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 38. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. MeiraGTx Recent Developments and Future Plans
Table 40. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 41. Sarepta Therapeutics Major Business
Table 42. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 43. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Sarepta Therapeutics Recent Developments and Future Plans
Table 45. Neurocrine Biosciences Company Information, Head Office, and Major Competitors
Table 46. Neurocrine Biosciences Major Business
Table 47. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 48. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Neurocrine Biosciences Recent Developments and Future Plans
Table 50. Voyager Therapeutics Company Information, Head Office, and Major Competitors
Table 51. Voyager Therapeutics Major Business
Table 52. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 53. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Voyager Therapeutics Recent Developments and Future Plans
Table 55. Asklepios Biopharmaceutical Company Information, Head Office, and Major Competitors
Table 56. Asklepios Biopharmaceutical Major Business
Table 57. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Solutions
Table 58. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Asklepios Biopharmaceutical Recent Developments and Future Plans
Table 60. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (USD Million) by Players (2019-2024)
Table 61. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Players (2019-2024)
Table 62. Breakdown of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 64. Head Office of Key Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players
Table 65. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Company Product Type Footprint
Table 66. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Company Product Application Footprint
Table 67. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy New Market Entrants and Barriers to Market Entry
Table 68. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (USD Million) by Type (2019-2024)
Table 70. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Share by Type (2019-2024)
Table 71. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Forecast by Type (2025-2030)
Table 72. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2024)
Table 73. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Forecast by Application (2025-2030)
Table 74. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
Table 75. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
Table 76. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
Table 77. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
Table 78. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2019-2024) & (USD Million)
Table 79. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2025-2030) & (USD Million)
Table 80. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
Table 83. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
Table 84. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
Table 87. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
Table 88. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
Table 89. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
Table 90. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Region (2019-2024) & (USD Million)
Table 91. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Region (2025-2030) & (USD Million)
Table 92. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
Table 93. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
Table 94. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
Table 95. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
Table 96. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2019-2024) & (USD Million)
Table 97. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2019-2024) & (USD Million)
Table 99. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type (2025-2030) & (USD Million)
Table 100. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2019-2024) & (USD Million)
Table 101. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Application (2025-2030) & (USD Million)
Table 102. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2019-2024) & (USD Million)
Table 103. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Country (2025-2030) & (USD Million)
Table 104. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Raw Material
Table 105. Key Suppliers of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Raw Materials
List of Figures
Figure 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Picture
Figure 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Type in 2023
Figure 4. Single-stranded AAV (ssAAV)
Figure 5. Self-complementary AAV (scAAV)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Application in 2023
Figure 8. Hemophilia Picture
Figure 9. Ophthalmology Picture
Figure 10. Lysosomal Storage Disorders Picture
Figure 11. Neurological Disorders Picture
Figure 12. Others Picture
Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Region (2019-2030)
Figure 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Region in 2023
Figure 18. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 20. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 21. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 22. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Players in 2023
Figure 24. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 25. Global Top 3 Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share in 2023
Figure 26. Global Top 6 Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share in 2023
Figure 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Share by Type (2019-2024)
Figure 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Type (2025-2030)
Figure 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Share by Application (2019-2024)
Figure 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Application (2025-2030)
Figure 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Type (2019-2030)
Figure 32. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Application (2019-2030)
Figure 33. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Country (2019-2030)
Figure 34. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 35. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 36. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 37. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Type (2019-2030)
Figure 38. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Application (2019-2030)
Figure 39. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Country (2019-2030)
Figure 40. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 41. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 42. United Kingdom Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 43. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 44. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 45. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Type (2019-2030)
Figure 46. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Application (2019-2030)
Figure 47. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Region (2019-2030)
Figure 48. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 49. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 50. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 51. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 52. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 53. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 54. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Type (2019-2030)
Figure 55. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Application (2019-2030)
Figure 56. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Country (2019-2030)
Figure 57. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 58. Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 59. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Type (2019-2030)
Figure 60. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Application (2019-2030)
Figure 61. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Country (2019-2030)
Figure 62. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 63. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 64. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2019-2030) & (USD Million)
Figure 65. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
Figure 66. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
Figure 67. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in 2023
Figure 70. Manufacturing Process Analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Figure 71. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
BioMarin Pharmaceutical Sangamo Therapeutics Amicus Therapeutics Roche Pfizer NightstaRx MeiraGTx Sarepta Therapeutics Neurocrine Biosciences Voyager Therapeutics Asklepios Biopharmaceutical
Related Reports
23 Jan 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
